24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring

Fogari, Roberto; Ambrosoli, S; Corradi, Luca; Esposti, Ezio Degli; Mos, L.; Nami, R; Nicrosini, F; Pessina, Achille C.; Salvetti, Antonio; Vaccarella, A.; Zanchetti, Alberto; Martin, Allison; Reeves, Richard

doi:10.1097/00004872-199715120-00020

Cited by 58 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidences of adverse events and adverse drug reactions in the irbesartan group were comparable to those in the placebo group. These results confirmed the safety of irbesartan shown in previous studies (9).…”

Section: Discussionsupporting

confidence: 92%

“…The results from the Italian study cannot be simply compared with those from the present study because of differences in dose of irbesartan (75 and 150 mg vs. 100 mg), treatment period (8 weeks vs. 6 weeks) and ABPM condition (outpatient vs. inpatient). In the Fogari et al study (9), the reduction in 24-h BP following administration of irbesartan 150 mg was 10.5 mmHg for systolic BP and 7.2 mmHg for diastolic BP, with T/P ratios of 0.68 and 0.76, respectively. The reductions in BPs in the Italian study tended to be greater, although the T/P ratio was similar.…”

Section: Discussionmentioning

confidence: 89%

“…Based on the findings of another ABPM study of irbesartan (9), it was estimated that the mean difference in the reduction in mean 24-h BP between the irbesartan group and placebo group would be 5.0 mmHg with a SD of 6.0 mmHg. Using these values, the required number of subjects to detect a difference between the two groups was estimated to be 23 per group (power of test: 80%, α=0.05, two-sided).…”

Section: Subjectsmentioning

confidence: 99%

See 2 more Smart Citations

A Randomized Trial of the Effect of an Angiotensin II Receptor Blocker SR47436 (Irbesartan) on 24-Hour Blood Pressure in Patients with Essential Hypertension

Kawano

Sato

Yoshinaga³

2008

Hypertens Res

View full text Add to dashboard Cite

The aim of this placebo-controlled, double-blind randomized study was to evaluate the duration of the effect of once-daily administration of irbesartan in patients with essential hypertension. After a placebo run-in baseline period (of 2-4 weeks), 79 patients were randomized to either irbesartan (one 100 mg tablet per day) or placebo, for 6 weeks. The primary outcome was the reduction in the mean 24-h blood pressure (BP) as assessed by ambulatory BP monitoring under standardized conditions. Seventy-six patients completed the study protocol. In the irbesartan group, the average reductions in 24-h systolic and diastolic BPs were 5.8

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 89%

Section: Subjectsmentioning

confidence: 99%

See 1 more Smart Citation

A Randomized Trial of the Effect of an Angiotensin II Receptor Blocker SR47436 (Irbesartan) on 24-Hour Blood Pressure in Patients with Essential Hypertension

Kawano

Sato

Yoshinaga³

2008

Hypertens Res

View full text Add to dashboard Cite

show abstract

“…The irbesartan 75-mg twice-daily and 150-mg once-daily regimens produced similar BP reductions, confirming that once-daily dosing with irbesartan is effective throughout the dosing interval. Trough seated office BP measurements (24 h after the last dose) were consistent with ABPM results (10).…”

Section: Previous Partsupporting

confidence: 81%

A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan

Waeber

2000

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

“…(In the ambulatory blood pressure study, 8 only the trough office blood pressures were used in the integrated analysis.) Trough measurements were performed 24Ϯ3 hours after the previous day's morning dose.…”

Section: Observation Methodsmentioning

confidence: 99%

Dose-Related Efficacy of Irbesartan for Hypertension

et al. 1998

Self Cite

View full text Add to dashboard Cite

Abstract-Results of eight multicenter, randomized, placebo-controlled, double-blind, parallel-group studies were pooled to assess the efficacy of the angiotensin II-receptor blocker irbesartan over the dose range of 1 to 900 mg. A total of 2955 adults with a seated diastolic blood pressure of 95 to 110 mm Hg were randomized to treatment with oral irbesartan once daily or placebo for 6 to 8 weeks. Office blood pressure was measured at trough (24Ϯ3 hours after the last dose) and peak (3Ϯ1 hours after the last dose) by mercury sphygmomanometry. Demographic characteristics (mean blood pressure; 151/101 mm Hg; mean age, 54 years; 63% male; and 82% white) were similar across all dose groups. After the groups were pooled, antihypertensive efficacy was assessed by therapeutic response (trough seated diastolic blood pressure Ͻ90 mm Hg or a reduction from baseline of Ն10 mm Hg) and by modeling of the maximum reductions in trough and peak seated diastolic and systolic blood pressure. Antihypertensive effects increased with increasing doses and reached a plateau at Ն300 mg. Irbesartan 150 mg provided placebo-subtracted reductions in trough seated systolic and diastolic blood pressure of Ϸ8 and Ϸ5 mm Hg, respectively, with 56% of patients displaying a favorable response.In conclusion, irbesartan provides clinically significant blood pressure lowering, with a clear relationship between (log) dose and antihypertensive effect. (Hypertension. 1998;31:1311-1316.)

show abstract

24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring

Cited by 58 publications

References 15 publications

A Randomized Trial of the Effect of an Angiotensin II Receptor Blocker SR47436 (Irbesartan) on 24-Hour Blood Pressure in Patients with Essential Hypertension

A Randomized Trial of the Effect of an Angiotensin II Receptor Blocker SR47436 (Irbesartan) on 24-Hour Blood Pressure in Patients with Essential Hypertension

A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan

Dose-Related Efficacy of Irbesartan for Hypertension

Contact Info

Product

Resources

About